If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can tirzepatide be used in patients with delayed gastric emptying?
Tirzepatide has not been studied in people with severe gastroparesis and is therefore not recommended in these patients.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide slows gastric emptying. The delay is largest after the first dose and this effect diminishes over time.1
The use of tirzepatide may be associated with gastrointestinal adverse reactions, sometimes severe.1
Tirzepatide has not been studied in patients with severe gastrointestinal disease and should be used with caution in these patients.1
In the SURPASS program, people were excluded from tirzepatide clinical trials if they had a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction).
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: May 14, 2022